Synchron’s Stentrode Brain-Computer Interface Receives Breakthrough Device Designation from FDA

SAN FRANCISCO & NEW YORK & MELBOURNE, Australia--(BUSINESS WIRE)--Synchron, a neurovascular bioelectronics medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for Stentrode, a fully-implantable medical device that can translate brain activity or stimulate the nervous system from the inside of a blood vessel, without the need for open brain surgery. The device, which has already been implanted in patients with upper-limb

Click to view original post